Maximising the Potential of Radiopharmaceuticals through Novel Targets, Expanded Isotopes & Supply, & Enhanced Dosimetry to Drive Efficacious Therapies From Bench to Approval
Radiopharmaceuticals are no longer an emerging promise, they are becoming a defining force in oncology. Once considered a niche modality, targeted radiopharmaceutical therapies are rapidly moving into the spotlight as one of the most promising approaches for precision cancer treatment. With major pharmaceutical companies investing heavily, pipelines expanding at pace, and clinical successes demonstrating the power of targeted radiation delivery, the field is transitioning from early validation to scale.
Momentum across the sector is undeniable. Breakthrough therapies continue to advance through the clinic, alpha‑emitting isotopes are unlocking new possibilities for highly potent tumour targeting, and the theranostic paradigm is redefining how patients are diagnosed and treated. As more assets progress into late‑stage trials and combination strategies gain traction, radiopharmaceuticals are positioned to play a central role in the next generation of oncology therapeutics.
Yet with this rapid growth comes a unique and complex set of challenges. Unlike traditional drug modalities, radiopharmaceutical development requires a tightly integrated ecosystem spanning isotope production, radiochemistry, manufacturing infrastructure, specialized clinical sites, and regulatory expertise.
This is why the 5th Targeted Radiopharmaceuticals Summit US returns in 2026 as the industry’s most comprehensive end-to-end meeting dedicated to advancing radioligand therapies from discovery through to commercialization. Taking place July 21–23, 2026 in San Diego, California, the summit will bring together 260+ leaders from across the radiopharmaceutical field, including biopharma innovators, nuclear medicine physicians, radiochemists, isotope suppliers, CDMOs, regulators, and investors, to tackle the scientific, clinical, and operational challenges shaping the field.
Over three days of technical discussions, strategic insights, and collaborative networking, attendees will explore the full lifecycle of targeted radiopharmaceutical development, from discovery and preclinical innovation through clinical translation, manufacturing scale-up, and supply chain resilience.
Whether you are developing the next generation of radioligand therapies, building isotope production capacity, advancing clinical trials, or supporting the infrastructure needed to bring these therapies to patients, the 5th Targeted Radiopharmaceuticals Summit US is where the community comes together to move the field forward. Join the experts shaping the future of targeted radioligand therapy and help define the next chapter of precision oncology
What's New for 2026?
Great opportunity to connect, network and catch-up on the latest views on targeted radiopharmaceuticals.
Grant Blouse, Chief Scientific Officer, Therapaint
I enjoyed the opportunity to interact with senior representatives of leading companies in the TRP space and the emphasis on networking and offline discussions.
Kent Iverson, Chief Technology Officer, Photinia Biosciences
Explore the Full Event Guide
- 260+ Attendees from World-Leading RLT Companies
- 66+ Speakers including Novartis, AstraZeneca, RayzeBio & Convergent Therapeutics
- 8+ Hours of Dedicated Networking alongside pioneers in the RLT industry
- 4 Tracks of Content: An agenda built for your team, spanning from Discovery to
CMC & Supply Chain - 22+ C-Suite Speakers with direct influence on their companies’ pipelines & decision-making
Official Partners
Lead Partner
Exhibition Partners
Program Partners
Hosting Partner
Attending Companies Include
Explore Related Events
Explore the Agenda
Discover how leading scientists and clinicians in TRP and radioligand therapy are redefining every stage of development - from target discovery and validation to isotope selection and commercialization strategy. Gain insight into the approaches shaping the next generation of radiopharmaceutical therapies and accelerating their path to the clinic.
Partner With Us
Engage directly with key decision-makers across imaging, radiochemistry, isotope development and more, who are actively seeking collaborations. Explore opportunities to accelerate the development of safer, more effective radiopharmaceuticals and contribute to projects that move quickly from concept to clinical application.
Join TRP Experts
Network with over 260 radiochemists, biologists, clinicians, and R&D leaders who are shaping the full RLT pipeline. Share expertise, exchange ideas, and collaborate across discovery, preclinical development, and clinical translation to advance therapies that can make a real impact for patients.